Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

NSABP/NRG Oncology and the UPMC Hillman Cancer Center

2 abstracts

Abstract
Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.
Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center,
Abstract
Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.
Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, SWOG, Hospital Clinic of Barcelona, Perlmutter Cancer Center, New York University Langone Health,